The quest to transform treatment for severe autoimmune diseases just got a significant boost. Oblenio Bio, a biotech firm focused on putting the promise of immune reset within reach for millions of patients, has secured $62.0M in Series B funding.
The company is developing T-cell engagers as a novel therapeutic approach. This strategy aims to address underlying disease pathophysiology and achieve immune reset, potentially offering a new path for those suffering from debilitating autoimmune conditions.
